JP2014520767A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520767A5
JP2014520767A5 JP2014517492A JP2014517492A JP2014520767A5 JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5 JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5
Authority
JP
Japan
Prior art keywords
group
atoms
hal
cyc
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517492A
Other languages
English (en)
Japanese (ja)
Other versions
JP6116554B2 (ja
JP2014520767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/002469 external-priority patent/WO2013004332A1/en
Publication of JP2014520767A publication Critical patent/JP2014520767A/ja
Publication of JP2014520767A5 publication Critical patent/JP2014520767A5/ja
Application granted granted Critical
Publication of JP6116554B2 publication Critical patent/JP6116554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517492A 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環 Expired - Fee Related JP6116554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505376P 2011-07-07 2011-07-07
US61/505,376 2011-07-07
PCT/EP2012/002469 WO2013004332A1 (en) 2011-07-07 2012-06-11 Substituted azaheterocycles for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014520767A JP2014520767A (ja) 2014-08-25
JP2014520767A5 true JP2014520767A5 (enExample) 2015-07-30
JP6116554B2 JP6116554B2 (ja) 2017-04-19

Family

ID=46354143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517492A Expired - Fee Related JP6116554B2 (ja) 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環

Country Status (9)

Country Link
US (1) US9199962B2 (enExample)
EP (1) EP2729459B1 (enExample)
JP (1) JP6116554B2 (enExample)
CN (1) CN103649074B (enExample)
AU (1) AU2012280725B2 (enExample)
CA (1) CA2840883C (enExample)
ES (1) ES2698847T3 (enExample)
IL (1) IL230218A (enExample)
WO (1) WO2013004332A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN104619686A (zh) 2012-08-23 2015-05-13 霍夫曼-拉罗奇有限公司 用于治疗癌症的新的苯基-吡啶/吡嗪酰胺
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
JP6412503B2 (ja) * 2012-11-21 2018-10-24 ピーティーシー セラピューティクス, インコーポレイテッド 置換逆ピリミジンBmi−1阻害剤
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2014138460A1 (en) 2013-03-07 2014-09-12 Northwestern University 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
TWI624467B (zh) 2013-10-14 2018-05-21 衛材R&D企管股份有限公司 選擇性經取代之喹啉化合物
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
EP3215497A4 (en) * 2014-11-04 2018-11-07 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
AU2018274723B2 (en) * 2017-05-26 2024-01-18 Cancer Research Technology Limited Benzimidazolone derived inhibitors of BCL6
AU2019253510B2 (en) 2018-04-13 2023-08-10 Cancer Research Technology Limited BCL6 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
CN115551840B (zh) 2020-05-19 2024-12-03 优迈特株式会社 含氟嘧啶化合物和含氟嘧啶酮化合物
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
US12522580B2 (en) 2021-11-12 2026-01-13 Unimatec Co., Ltd. Fluorine-containing pyrimidine compounds, harmful fungus control agent, and method for producing fluorine-containing pyrimidine compounds
CN120794959A (zh) * 2022-04-29 2025-10-17 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
CN120202201A (zh) * 2022-11-04 2025-06-24 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
EP4741386A1 (en) * 2023-07-05 2026-05-13 Jiangsu Yahong Meditech Co., Ltd. Pyrimidine compound, preparation method therefor and medical use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163647T1 (de) * 1993-08-26 1998-03-15 Ono Pharmaceutical Co 4-aminopyrimidin derivate
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU9458401A (en) * 2000-09-20 2002-04-02 Ortho Mcneil Pharm Inc Pyrazine derivatives as modulators of tyrosine kinases
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
KR20060032190A (ko) * 2003-07-02 2006-04-14 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널의 조절제로서 유용한 피리미딘
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1735319B1 (en) * 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CN103087043A (zh) * 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
JP5642973B2 (ja) 2007-03-22 2014-12-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Jak阻害薬として有用なn−複素環式化合物
US20090048282A1 (en) * 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027736A2 (en) 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
WO2009039542A2 (en) 2007-09-24 2009-04-02 Fibrex Medical Research & Development Gmbh Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak
JP2010126496A (ja) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp 複素環化合物
HRP20140265T1 (hr) 2009-02-06 2014-04-25 Nippon Shinyaku Co., Ltd. Derivat aminopirazina i odgovarajuä†i lijek
WO2010126922A1 (en) 2009-04-30 2010-11-04 Glaxosmithkline Llc Benzimidazolecarboxamides as inhibitors of fak
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods

Similar Documents

Publication Publication Date Title
JP2012506389A5 (enExample)
JP2013501047A5 (enExample)
JP2016503797A5 (enExample)
AR118341A2 (es) Mezclas fungicidas ternarias
JP2015536947A5 (enExample)
JP2012532899A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2014508753A5 (enExample)
JP2012092103A5 (enExample)
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
JP2014508811A5 (enExample)
JP2015522650A5 (enExample)
JP2012516871A5 (enExample)
JP2018533593A5 (enExample)
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
HRP20161103T1 (hr) Kemijski spojevi
JP2017501237A5 (enExample)
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2012508252A5 (enExample)
JP2011219498A5 (enExample)
JP2015535847A5 (enExample)
JP2014511891A5 (enExample)
JP2013532668A5 (enExample)